We are pleased and honored to have the following impressive group of the country’s top retinal disease thought leaders serve on our scientific advisory board.

Joan W. Miller, M.D.

Chair, Department of Ophthalmology, Harvard Medical School and Chief of Ophthalmology, Massachusetts Eye and Ear and Mass General Hospital

Full Bio

Allen Ho, M.D.

Director, Clinical Retina Research Unit and Retinal Surgeon, Wills Eye Hospital; Professor of Ophthalmology at Thomas Jefferson University School of Medicine

Full Bio

ONL Therapeutics Announces Formation of Scientific Advisory Board

Renowned Retinal Disease Thought Leaders to Help Guide Development of Novel Vision Protection Technology in Age-Related Macular Degeneration (AMD) and Retinal Detachment

ANN ARBOR, MI – October 14, 2015
ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced the formation
of a scientific advisory board (SAB) comprised
of five of the world’s premier retinal disease thought leaders.

Naresh Mandava, M.D.

Sue Anschutz-Rodgers Chair in Retinal Diseases and Chair, Department of Ophthalmology, University of Colorado

Full Bio

Charles C. Wykoff, M.D., Ph.D.

Director of the Greater Houston Retina Research Foundation with Retina Consultants of Houston

Full Bio

ONL has assembled an impressive group of advisors spanning critical scientific and operational areas including clinical research and development, pharmacology, manufacturing and regulatory strategy.

Contact Us

Start typing and press Enter to search